Rhizen Pharmaceuticals, TG Therapeutics collaborate on PI3K delta inhibitor
As part of the collaboration, the companies will develop TGR-1202 on a worldwide basis, excluding India, in the areas of hematologic malignancies and autoimmune disease. Rhizen will also
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.